The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
The AHA June 16 responded to a request for information on the health technology ecosystem from the Centers for Medicare & Medicaid Services and Assistant…
Headline
The Joint Commission June 11 announced a new partnership with the Coalition for Health AI to help accelerate the development and adoption of best practices and…
Headline
The National Security Agency, Cybersecurity and Infrastructure Security Agency and international partners May 22 released guidance on securing data used for…
Headline
The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing projects using artificial…